Final results of a phase 3 trial confirm the progression-free survival (PFS) benefit of adding short-term androgen suppression to radiotherapy as salvage treatment for men who experience rising PSA following radical prostatectomy for prostate cancer (PCa), investigators concluded in a paper published in Lancet Oncology.